Net Margin

-9 937.8%
Current
Improving
by 173.8%
vs 3-y average of -10 111.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-9 937.8%
=
Net Income
$-48.5m
/
Revenue
$354k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-9 937.8%
=
Net Income
CA$-48.5m
/
Revenue
$354k

Peer Comparison

Country Company Market Cap Net
Margin
CA
IMV Inc
TSX:IMV
9.2m CAD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.8B USD
Loading...

Market Distribution

Lower than 95% of companies in Canada
Percentile
5th
Based on 4 909 companies
5th percentile
-9 937.8%
Low
-9 940 586.9% — -85.9%
Typical Range
-85.9% — 5.5%
High
5.5% — 60 777.6%
Distribution Statistics
Canada
Min -9 940 586.9%
30th Percentile -85.9%
Median -7.8%
70th Percentile 5.5%
Max 60 777.6%

IMV Inc
Glance View

Market Cap
9.2m CAD
Industry
Biotechnology

IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 97 full-time employees. The company went IPO on 2007-10-24. The firm is using its DPX delivery technology to achieve targeted immune activation. The Company’s lead candidate, maveropepimut-S, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its other candidates include DPX-RSV and DPX-COVID-19. Its DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.

IMV Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-9 937.8%
=
Net Income
$-48.5m
/
Revenue
$354k
What is IMV Inc's current Net Margin?

The current Net Margin for IMV Inc is -9 937.8%, which is above its 3-year median of -10 111.7%.

How has Net Margin changed over time?

Over the last 3 years, IMV Inc’s Net Margin has decreased from -3 786.1% to -9 937.8%. During this period, it reached a low of -25 951.2% on Jun 30, 2022 and a high of -3 786.1% on Dec 31, 2019.

Back to Top